WO2016156639A1 - Formulación tópica oftálmica de antagonistas del receptor de la endotelina - Google Patents
Formulación tópica oftálmica de antagonistas del receptor de la endotelina Download PDFInfo
- Publication number
- WO2016156639A1 WO2016156639A1 PCT/ES2016/070197 ES2016070197W WO2016156639A1 WO 2016156639 A1 WO2016156639 A1 WO 2016156639A1 ES 2016070197 W ES2016070197 W ES 2016070197W WO 2016156639 A1 WO2016156639 A1 WO 2016156639A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- bosentan
- ophthalmic
- diabetes
- aqueous solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 238000009472 formulation Methods 0.000 title claims abstract description 70
- 230000000699 topical effect Effects 0.000 title claims abstract description 19
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title claims abstract description 16
- 239000002308 endothelin receptor antagonist Substances 0.000 title claims abstract description 16
- 229960003065 bosentan Drugs 0.000 claims abstract description 56
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 48
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 32
- -1 atrasentran Chemical compound 0.000 claims abstract description 30
- 230000002207 retinal effect Effects 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000032683 aging Effects 0.000 claims abstract description 14
- 229960002414 ambrisentan Drugs 0.000 claims abstract description 14
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims abstract description 14
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960001039 macitentan Drugs 0.000 claims abstract description 14
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960002578 sitaxentan Drugs 0.000 claims abstract description 14
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229950000584 tezosentan Drugs 0.000 claims abstract description 14
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims abstract 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 25
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 229960000281 trometamol Drugs 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 12
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004327 boric acid Substances 0.000 claims description 11
- 238000009736 wetting Methods 0.000 claims description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 claims description 7
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002353 niosome Substances 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229920002807 Thiomer Polymers 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229940068965 polysorbates Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims 1
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 51
- 210000001525 retina Anatomy 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 16
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 15
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 description 15
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 206010012689 Diabetic retinopathy Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 8
- 230000004914 glial activation Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940036810 bosentan monohydrate Drugs 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 206010018341 Gliosis Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007387 gliosis Effects 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 2
- 229940093541 dicetylphosphate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical group 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 102000030168 Endothelin A Receptor Human genes 0.000 description 1
- 108010090549 Endothelin A Receptor Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical group 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention belongs to the field of medicine and refers to topical ophthalmic formulations comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof. , more preferably bosentan, as active ingredient for the treatment of ocular disorders induced by metabolic diseases, such as diabetes, and / or aging.
- endothelin receptor antagonist preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof.
- bosentan as active ingredient for the treatment of ocular disorders induced by metabolic diseases, such as diabetes, and / or aging.
- Diabetes is a chronic disease characterized by the presence of hyperglycemia that is triggered when the body loses its ability to produce enough insulin or use it effectively.
- type 1 There are two main types of diabetes: type 1 and type 2.
- type 2 diabetes is the most common type of diabetes and usually occurs in adults, but more and more cases of children and adolescents.
- Diabetes can cause serious late complications that are classified into microangiopathic (retinopathy, neuropathy and diabetic nephropathy) and macroangiopathic (cardiovascular disease).
- Diabetic retinopathy is the most frequent complication of diabetes and the main cause of decreased visual acuity and blindness in the working-age population in developed countries.
- the incidence of DR increases with the time of evolution of diabetes.
- 90% of patients with type 1 diabetes and 60% of patients with type 2 diabetes have some degree of DR at 20 years of diabetes.
- the prevalence of DR in western countries is quite similar and is around 30% and in 10% of cases the DR is in advanced stages that seriously threaten vision, as described in Yau et al., Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care, 2012, 35,556-64.
- RD has been classically considered a disease of the microcirculation of the retina.
- Retinal neurodegeneration early pathology in diabetes, Clin. Exper. Ophthalmol., 2000, 28, 3-8
- retinal neurodegeneration is an early event in the pathogenesis of DR that participates in abnormalities that occur in microcirculation.
- the main characteristics of retinal neurodegeneration apoptosis and glial activation
- retinal neurodegeneration produces functional abnormalities, such as loss of color discrimination and contrast sensitivity.
- US2003 / 0176356 describes a pharmaceutical composition containing endothelin antagonists, such as bosentan, but for the treatment of a very different pathology, such as glaucoma.
- endothelin antagonists such as bosentan
- This document describes general formulations that have not demonstrated their viability. In fact, they are applied in a general way saying that they can be used for any endothelin inhibitor, when the galenic practice has shown that the same formulation developed for a specific active principle is not suitable for another active principle, even if it is from the same pharmacological family , since a small change in its molecular structure presupposes the modification of its galenic, physical and chemical characteristics. In this case, it can be affirmed that the formulations indicated in this document would not allow obtaining a viable and stable solution in time, not having proved its correct obtaining nor its viability for the application by ophthalmic route.
- the object of the present invention is the use of an ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably, as active ingredient for the manufacture of a medicament for the prevention and / or treatment of retinal neurodegeneration induced by diabetes and / or aging, or a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as an active ingredient for use in the prevention and / or treatment of neurodegeneration of the retina induced by diabetes and / or aging, or a method of prevention and / or treatment of neu Regeneration of the retina induced by diabetes and / or aging comprising the administration of a therapeutically effective
- an ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan .
- the object of the present invention is the use of an ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably, as active ingredient for the manufacture of a medicament for the prevention and / or treatment of retinal neurodegeneration induced by diabetes and / or aging.
- endothelin receptor antagonist preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably, as active ingredient for the manufacture of a medicament for the prevention and / or treatment of retinal neurodegeneration induced by diabetes and / or aging.
- an ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, for use in the prevention and / or treatment of neurodegeneration of the retina induced by diabetes and / or aging.
- endothelin receptor antagonist preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan
- Also part of the invention is a method of treating retinal neurodegeneration induced by diabetes and / or aging comprising the administration of a therapeutically effective amount of an ophthalmic topical formulation comprising at least one receptor antagonist of the endothelin, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan , as an active ingredient according to the different embodiments of the formulation described herein.
- an ophthalmic topical formulation comprising at least one receptor antagonist of the endothelin, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan , as an active ingredient according to the different embodiments of the formulation described herein.
- terapéuticaally effective amount refers to the amount or dose of active compound or compounds or a composition herein that will lead to one or more desired effects, in particular therapeutic effects.
- An effective amount or a therapeutically effective amount of a substance may vary depending on factors, such as the pathological state, age, sex and weight of the individual, and the ability of the substance to elicit a desired response in the individual.
- the dosage regimen can be adjusted to provide the optimal therapeutic response (such as, prolonged beneficial effects). For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the requirements of the therapeutic situation.
- an ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as an active ingredient, surprisingly, prevents diabetes-induced retinal neurodegeneration and is appropriate for the treatment of the initial stages of said neurodegeneration.
- Said formulation allows the penetration of the active substance through the ophthalmic mucosa to the retina, which is where it performs its therapeutic action.
- the ocular topical route is not considered as an adequate route of administration to treat RD, because it is considered that the drugs administered by this route do not reach the retina, the tests carried out show that the formulation of the present invention It reaches the retina and prevents neurodegeneration.
- neurodegeneration of the retina is characterized by the activation of glia cells (reactive gliosis) and death by apoptosis of neurons, mainly neurons in the ganglion cell layer.
- retinal neurodegeneration defects in contrast sensitivity and visual fields, as well as difficulty adapting to darkness, as described in Di Leo et al., Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy, Diabetologia, 1994, 37, 91 1-916, and in Frost-Larsen et al., Valué of electroretinography and dark adaptation as prognostic tools in diabetic retinopathy, Dev. Ophthalmol., 1981, 2, 222-234. From the clinical point of view, early identification of neurodegeneration is important in order to start drug-based treatment with a neuroprotective effect.
- the initial stages of retinal neurodegeneration can be detected by Ophthalmologic examination using frequency domain optical coherence tomography (FD-OCT) or multifocal electroretinogram (mfERG), as described in Simó et al., op. cit. These examinations are not included among the routine ophthalmological exams that are performed periodically to diabetic patients to diagnose RD, since there are currently no treatments for RD based on neuroprotection.
- FD-OCT frequency domain optical coherence tomography
- mfERG multifocal electroretinogram
- the use of the ophthalmic topical formulation comprising at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, is for the prevention and / or treatment of diabetes-induced retinal neurodegeneration.
- endothelin receptor antagonist preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan
- Preferably said use is for the prevention and / or treatment of the initial stages of retinal neurodegeneration induced by diabetes and / or aging.
- Preferably said use is for the prevention and / or treatment of the initial stages of diabetes-induced retinal neurodegeneration.
- Topical ophthalmic formulation
- the ophthalmic topical formulation of the invention can be in liquid, semi-solid or solid pharmaceutical form.
- the liquid pharmaceutical form may be, for example, solution, suspension, fluid emulsion, fluid gel, microemulsion, nanoemulsion, or colloidal system.
- the semi-solid pharmaceutical form may be, for example, ointment, cream, ointment, gel, or paste).
- the solid pharmaceutical form may be, for example, ophthalmic implant, poultice, or dressing.
- the ophthalmic topical formulation is a liquid pharmaceutical form, more preferably an aqueous solution.
- the ophthalmic topical formulation is an aqueous solution comprising:
- a pharmaceutically acceptable humectant solvent selected from the group consisting of polyethylene glycol (PEG), propylene glycol, glycerin, and mixtures of the thereof, and / or selected from the group consisting of polyoxyethylenated derivatives of castor oil (may be obtained commercially, for example under the name Cremophor ® RH40 supplied by BASF), stearates, polyoxyethylene glycol, polysorbates, poloxamers solubilizer , glycerin, medium-chain Ce-Cio triglycerides, and mixtures thereof;
- a pharmaceutically acceptable pH regulator system to adjust the aqueous solution to a pH between 3.5 and 10.5.
- Said aqueous solution comprises water as solvent.
- the active substance of the present invention is at least one endothelin receptor antagonist, preferably chosen from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof.
- the active ingredient is 4- (1, 1- dimethylethyl) -N- [6- (2-hydroxyethoxy) -5- (2-methoxyphenoxy) [2,2'-bipyrimidin] Benzenesul-Fonamide, which corresponds to the international common denomination of Bosentan.
- bosentan is described in Canadian patent application CA-A-2071193 of Hoffmann-La Roche, and is an endothelin receptor antagonist, which is used in medicine as an antihypertensive agent, especially in the treatment of hypertension. pulmonary.
- bosentan refers to bosentan, its hydrates and its salts, such as, for example, bosentan monohydrate, or the sodium salt of bosentan.
- bosentan monohydrate is preferably used.
- bosentan expressed as bosentan, is generally comprised between 0.1% and 5% in (w / v) with respect to the total volume of the formulation, preferably between 0.2% and 2% and even more preferably between 0.5% and 1%.
- the active ingredient can be found incorporated in the form of microparticles, nanoparticles, liposomes or niosomes.
- the formulation of the invention comprises bosentan in combination with another active ingredient such as, for example, corticosteroids, prostaglandins, growth factors, anti-VEGF factors, or peptides.
- bosentan is used in combination with growth factors.
- the formulation of the invention comprises a pharmaceutically acceptable humectant solvent selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and mixtures thereof.
- a humectant solvent in the context of the invention, is a compound that has solvent and humectant properties.
- polyethylene glycol a name that designates a wide family of polymers with different molecular weights, obtained by condensation of ethylene oxide and water in the presence of a catalyst.
- the formula of said polymers can be represented as H (OCH2CH2) nOH, where n represents the average number of oxyethylene groups.
- PEG is widely used in pharmaceutical compositions, including parenteral, topical, ophthalmic, oral, and rectal formulations, since it is a stable compound that is essentially non-irritating to the skin. It is also a hydrophilic compound, easily soluble in water.
- the appropriate PEG for use in the formulation of the invention can have a molecular weight between 300 and 35,000, preferably between 600 and 20,000, more preferably between 1000 and 8000, even more preferably between 3000 and 6000, and still more preferably about 4000
- PEG 200 means a PEG having an approximate average molecular weight of 200.
- the PEG is liquid or solid.
- PEGs with an average molecular weight of up to 800 are liquid at temperature ambient, the PEG 1000 melts at a temperature between 37 ° C and 40 ° C, and the PEG 4000 melts between 50 ° C and 58 ° C.
- PEG can be obtained commercially, for example, under the name Carbowax ® supplied by the company Dow Chemical.
- Propylene glycol is a colorless, transparent, viscous, and practically odorless liquid, which is obtained by hydrolysis of propylene oxide.
- Glycerin is also a colorless, transparent, viscous and practically odorless liquid, with a slight sweet taste.
- PEG and / or propylene glycol are used as the wetting solvent, and even more preferably it is PEG 4000.
- the content of the wetting solvent is usually between 1% and 49% in (w / v) with respect to the total volume of the formulation, preferably between 5% and 40%, more preferably between 10% and 30%, and even more preferably between 15% and 25%.
- the formulation of the invention comprises a pharmaceutically acceptable regulatory system for adjusting the pH of the aqueous solution to a value between 3.5 and 10.5, preferably between 4.0 and 8.5, more preferably between 6.0 and 8 , 2, more preferably between 7.0 and 8, 1, and even more preferably between 7.5 and 8.0.
- the appropriate regulatory system to obtain said pH can be selected by one skilled in the art from among the regulatory systems used in pharmaceutical formulations such as, for example, citrus / citrate regulatory solutions, phosphate regulatory solutions, boric-borate regulatory solutions, and mixtures thereof.
- Said regulatory system may include amino acids and / or aminated substances.
- the pH regulating system is preferably selected from the regulatory system formed by boric acid, glycine and an amine selected from the group consisting of tromethamine, arginine, lysine, methylglucamine, and mixtures thereof; the citric acid / citrate system, and the phosphate system.
- the pH regulating system is formed by boric acid, glycine and an amine selected from the group consisting of tromethamine, arginine, lysine, methylglucamine, and mixtures thereof; or the citric acid / citrate system. More preferably the pH regulating system is formed by boric acid, glycine and an amine selected from the group consisting of tromethamine, arginine, lysine, methylglucamine, and mixtures thereof, and even more preferably the pH regulating system is formed by boric acid, glycine and trometamol.
- the amount of pH regulating system necessary to adjust the pH to the desired value is a common task that does not represent any difficulty for the person skilled in the art.
- the boric acid content is between 0.1% and 10% in (w / v) with respect to the total volume of the formulation, more preferably between 0.5% and 5%, and even more preferably between 0.75% and 1.5%
- the glycine content is between 0.5% and 20% in (w / v) with respect to the total volume of the formulation, more preferably between 0.75% and 10%, and even more preferably between 1.5% and 2.5%
- the amine content is between 0.1% and 25% in (w / v) with respect to the total volume of the formulation, preferably between 0.5% and 10%, more preferably between 0 , 75% and 5%, and even more preferably between 1% and 2.5%.
- the ophthalmic topical formulation of the invention may include other components such as, for example, surfactants, cosolvents, viscosizers, preservatives, isotonic agents, isoosmotizing agents, absorption enhancers of the active ingredient, mucoadhesive polymers, non-mucoadhesive polymers, chelants, stabilizers, antioxidants , and mixtures thereof.
- surfactants there may be mentioned, for example, polyethoxylated glycerides, polysorbates, poloxamers, sodium lauryl sulfate, phospholipids, such as phosphatidylcholine or phosphatidyl glycerol and its derivatives, polyoxyethylene hydrogenated castor oil, fatty acids polyoxyethylene, mixtures of mono-, di, and triglycerides of optionally polyoxyethylene fatty acids, and mixtures thereof.
- co - solvents or solubilizers may be mentioned, for example, polyoxyethylene derivatives of castor oil (can be obtained commercially, for example under the name Cremophor ® RH40 supplied by BASF), polyoxyethylene stearates, polyethylene glycol, polysorbates, poloxamers, glycerin, medium-chain Ce-Cio triglycerides, and mixtures thereof.
- polyoxyethylene derivatives of castor oil can be obtained commercially, for example under the name Cremophor ® RH40 supplied by BASF
- polyoxyethylene stearates polyethylene glycol
- polysorbates poloxamers
- glycerin glycerin
- medium-chain Ce-Cio triglycerides and mixtures thereof.
- viscosifying agents there may be mentioned, for example, polyvinyl alcohol, methyl cellulose, hydroxypropyl methylcellulose, carbomers, polyethylene glycol, and mixtures thereof.
- preservatives may be mentioned, for example, benzalkonium chloride, boric acid, benzoic acid, C1-C4 alkyl chain esters of p-hydroxybenzoic acid, chlorobutanol, benzyl alcohol, phenylethyl alcohol, organometallic derivatives of mercury, polyquartenium as polyquaternium 1 , and mixtures thereof.
- isotonizing and isoosmotizing agents there may be mentioned, for example, inorganic salts such as sodium chloride, dextrose, trehalose, mannitol, amino acids, and mixtures thereof.
- absorption enhancers of the active ingredient may be mentioned, for example, saponin, fatty acid, C1-C4 alkyl chain ester of a fatty acid, pyrrolidone, polyvinylpyrrolidone, pyruvic acid, pyroglutamic acid, and mixtures thereof.
- mucoadhesive polymers there may be mentioned, for example, hyaluronic acid, polygalacturonic acid, polyacrylic acid, carboxymethylamilose, carboxymethylquitin, chondroitin sulfate, methylcellulose, gelatin, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose, carboxymethylcellulose gellan gum, carrageenans, alginates, pectin, poloxamer, and mixtures thereof.
- non-mucoadhesive polymers there may be mentioned, for example, polyvinyl alcohol.
- chelants there may be mentioned, for example, disodium edetate, and disodium chromoglycolate.
- stabilizers of the active ingredient there may be mentioned, for example, citric acid, ascorbic acid, glycine, arginine, lysine, and mixtures thereof.
- Antioxidants may include, for example, sodium metabisulfite, sodium bisulfite, acetylcysteine, ascorbic acid, and mixtures thereof.
- gelling agents for example, carbomers, methyl cellulose, hydroxypropyl methylcellulose, poloxamers, polyacrylic acid, alginate, chitosan, xanthan gum, gellan gum, xyloglycans, and mixtures thereof can be mentioned.
- esters of fatty acids and glycerin for example, esters of fatty acids and glycerin, polyoxyethylene alcohols, polyoxyethylene fatty acids, polyoxyethylene derivatives of castor oil, Ce-Cio medium chain triglycerides, and mixtures thereof.
- ointments and ointments can be mentioned, for example, petrolatum, paraffins, high molecular weight polyethylene glycols, silicones, and mixtures thereof.
- the compounds used to prepare the microparticles, nanoparticles, liposomes, or niosomes are, for example, polylactic acid, poly (lactic-co-glycolic acid), polystyrenes, chitosan, albumin, gelatin, lectins, cyanoacrylates, polycaprolactones, methacrylates , polyacrylamides, alginates, dextrans, agarose, polyoxyethylene sorbitan derivatives, cholesterol, polyethoxylated fatty alcohol, dicetyl phosphate, phosphatidylcholine and mixtures thereof.
- polylactic acid poly (lactic-co-glycolic acid)
- polystyrenes chitosan
- albumin albumin
- gelatin lectins
- cyanoacrylates polycaprolactones
- methacrylates polyacrylamides
- alginates dextrans
- agarose polyoxyethylene sorbitan derivatives
- cholesterol polyethoxylated fatty alcohol
- the ophthalmic formulation of the invention can be sterile, then dispensing with the preservatives referred to above.
- the formulation can be prepared according to the pharmaceutical technique that the person skilled in the art deems most suitable, either by aseptic preparation, sterilizing filtration, or sterilization of the final formulation.
- the ophthalmic topical formulation of the invention is an aqueous solution comprising: 1) between 0.1% and 0.5% (w / v), preferably between 0.2% and 2%, and more preferably between 0.5% and 1% of bosentan;
- tromethamine between 0.1% and 25% (w / v), preferably between 0.5% and 10%, more preferably between 0.75% and 5%, and even more preferably between 1 % and 2.5% of an amine selected from the group consisting of tromethamine, arginine, lysine, methylglucamine, and mixtures thereof, preferably tromethamine;
- the pH of the aqueous solution is between 3.5 and 10.5, preferably between 4.0 and 8.5, more preferably between 6.0 and 8.2, more preferably between 7.0 and 8.1 , and even more preferably between 7.5 and 8.0; and where the percentages (w / v) are expressed with respect to the total volume of the formulation.
- the formulation of the invention consists essentially of the above components with the amounts reflected, and in the form of an aqueous solution.
- the ophthalmic topical formulation of the invention comprises:
- pH of the aqueous solution is between 3.5 and 10.5, preferably between 4.0 and 8.5, more preferably between 6.0 and 8.2, more preferably between 7.0 and 8.1 , Y even more preferably between 7.5 and 8.0; and where the percentages (w / v) are expressed with respect to the total volume of the formulation.
- the ophthalmic topical formulation of the invention comprises:
- the pH of the aqueous solution is between 3.5 and 10.5, preferably between 4.0 and 8.5, more preferably between 6.0 and 8.2, more preferably between 7.0 and 8.1 , and even more preferably between 7.5 and 8.0; and where the percentages (w / v) are expressed with respect to the total volume of the formulation.
- the formulation of the invention consists essentially of the above components and in the amounts reflected and in the form of an aqueous solution.
- the process for preparing the formulation of the invention is a standard procedure within pharmaceutical technology.
- the process is started by introducing a part of the water into the reactor, and then the wetting or solubilizing solvent (s) (s) are added consecutively and with stirring at room temperature. s), the components of the pH regulating system, and the active substance.
- the active ingredient intercalated between the components of the pH regulating system can also be added, to facilitate its dissolution. It is recommended that after each addition the reactor contents are stirred until the complete dissolution of the added component is observed.
- the ophthalmic topical formulation of the invention was administered directly to the eyes of diabetic mice (db / db).
- db / db diabetic mice
- These animals have a mutation in the gene that codes for the leptin receptor and represent an obesity-induced type 2 diabetes model, as described in, for example, Duval et al., Characterization of db / db mice for efficacy / safety pharmacology assessment of antidiabetic drugs, Safety Pharmacology Society Annual Meeting, Phoenix, 2012.
- the formulation of the invention was administered for a period of 14 days, twice a day, and after the test period a lower glial activation and a reduction of apoptosis was observed in all the retinal layers of animals treated with bosentan .
- Glial activation is the inflammatory response of glia cells (neuron support cells) that occurs when there is a noxa (for example, diabetes) that damages the retina.
- glia cells neuron support cells
- Neural death due to apoptosis represents the final phase of the neurodegenerative process of the retina.
- bosentan prevents neuroinflammation of the retina and neuronal death induced by diabetes.
- the topical ophthalmic formulation of the invention allows bosentan to penetrate the retina through the ophthalmic mucosa and exert its therapeutic action to prevent and / or treat retinal neurodegeneration.
- the solution was flush to 100 mL by adding deionized water in sufficient quantity.
- the solution was filtered with filter paper, and a colorless and transparent solution was obtained, with a pH of 8.06.
- the solution was packaged in eye dropper bottles with a volume of 5 mL.
- the amounts of the components are expressed in grams, and the amount of water refers to 100 mL.
- Bosentan 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Cremophor ®
- Alcohol 0.5 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 phenylethyl c.s.p. c.s.p. c.s.p.
- ophthalmic topical compositions were prepared in the form of lipophilic ointments described in Table 5:
- Example 41 Topical ophthalmic solution with bosentan nanoparticles
- the nanoparticles were prepared by the solvent evaporation technique.
- a solution of 120 mg of 50:50 PLGA in 60 mL of ethyl acetate was prepared.
- An aqueous solution of 50 mL of water with 12 mg of bosentan monohydrate and 0.5 mg of polyvinyl alcohol was incorporated under turboagitation.
- the resulting mixture was left under continuous stirring and under vacuum for 2 hours.
- the resulting preparation was ultracentrifuged and washed with water three times, to separate the nanoparticles from the medium.
- the nanoparticles were dried in a vacuum oven and after titration, an amount sufficient for a concentration of 0.5 mg / 100 mL of bosentan monohydrate was dispersed in an isotonic aqueous solution.
- Example 42 Topical ophthalmic solution with bosentan niosomes
- Niosomes were prepared by the thin film hydration technique.
- the polyoxyethylene sorbitan monostearate was mixed with 20 moles of ethylene oxide, cholesterol and the dicetyl phosphate in a 1: 0.5: 0.1 molar ratio in a spherical flask with 10 mL of chloroform. It was left at 60 ° C and under reduced pressure on a rotary evaporator at 120 rpm until complete evaporation.
- the thin film that formed in the flask was hydrated with 12 mL of phosphate buffer solution pH 7.4 containing 5 mg of bosentan monohydrate.
- the niosome suspension was allowed to cool 12h at 4 ° C and then filtered by 0.22 ⁇ ⁇ nylon filter.
- Example 43 Treatment with the ophthalmic topical formulation
- db / db rats (Har ⁇ an Laboratories, Inc.) were used, which were divided into two groups: 6 of these rats were treated with a formulation of the invention, and 6 rats with a solution of sodium chloride, as described below. 6 non-diabetic (db / +) rats of the same age were also used as the control group.
- a drop (5 ⁇ ) of the formulation of Example 1 or a drop of vehicle (5 ⁇ of a 0.9% weight / volume sodium chloride solution) was administered by syringe directly on the upper corneal surface of each eye of the 12 rats db / db, twice a day, for 14 days.
- Glial activation was evaluated by scanning confocal laser microscopy using specific antibodies against GFAP (glial fibrillar acidic protein).
- the retina sections were fixed in acidic methanol at a temperature of -20 ° C for 2 min, followed by three washes with phosphate regulatory solution (PBS) of 5 min each.
- Retina sections were permeabilized with Tris buffer (TBS) Triton ® X-100 and 0.025% incubated for 2 hours, at room temperature, in a blocking solution consisting of 1% BSA (bovine serum albumin) and 10% goat serum in 10% PBS.
- BSA bovine serum albumin
- Retina sections were incubated with rabbit anti-GFAP antibody (Abcam Ltd, Cambridge, UK; 1: 500 dilution in blocking solution prepared) overnight at a temperature of 4 o C in a humid atmosphere. After three washes with PBS solution, 5 minutes each, the retinal sections were incubated with the Alexa 488 goat anti-rabbit secondary antibody (Invitrogen, San Diego CA, USA) at a 1: 200 dilution prepared in blocking solution. The retinal sections were washed three times with PBS, contracted with Hoechst, mounted with fluorescence mounting medium (Prolong, Invitrogen) and covered with a coverslip. Comparative digital images of the samples were recorded using a scanning laser confocal microscope (FluoView FV 1000, Olympus) using identical brightness and contrast settings.
- the score was evaluated in the retina of each of the animals and in a minimum of 10 sections per retina.
- Table 8 shows the degree of glial activation (percentage for each GFAP expression score) for the three types of animals (control, db / db treated with vehicle, and db / db treated with bosentan): TABLE 8
- GFAP expression was mostly limited to the retinal ganglion layer (GCL) and, therefore, the GFAP score was ⁇ 2.
- Example 45 Immunohistochemical analysis for the evaluation of apoptosis
- the retinal cryosections were permeabilized by incubation for 2 min on ice with a solution of 0.1% Triton ® X-100 and 0.1% freshly prepared sodium citrate.
- the secondary antibody was Alexa 488 goat anti-rabbit (Invitrogen, San Diego CA, USA).
- the excitation wavelength was 488 nm and the detection range used from 515 to 565 nm, which corresponds to the green color.
- the assessment was carried out in the retina of each of the animals and in a minimum of 10 sections per retina.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/561,922 US10716750B2 (en) | 2015-03-27 | 2016-03-22 | Topical ophthalmic formulations of endothelin receptor antagonists |
EP16720451.0A EP3275429A1 (en) | 2015-03-27 | 2016-03-22 | Topical ophthalmic formulation of endothelin receptor antagonists |
CN202311521053.3A CN117582396A (zh) | 2015-03-27 | 2016-03-22 | 局部眼用制剂的用途 |
MX2017012428A MX2017012428A (es) | 2015-03-27 | 2016-03-22 | Formulacion topica oftalmica de antagonistas del receptor de la endotelina y sus usos. |
KR1020177027527A KR102578102B1 (ko) | 2015-03-27 | 2016-03-22 | 엔도텔린 수용체 길항제의 국소 안용 제형 |
CN201680018617.3A CN107454841A (zh) | 2015-03-27 | 2016-03-22 | 内皮素受体拮抗剂的局部眼用制剂及其用途 |
BR112017019792A BR112017019792A2 (pt) | 2015-03-27 | 2016-03-22 | formulação oftálmica tópica e uso da mesma. |
JP2018500867A JP6768780B2 (ja) | 2015-03-27 | 2016-03-22 | エンドセリン受容体の拮抗薬の局所用眼科製剤およびそれらの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201530409A ES2584534B1 (es) | 2015-03-27 | 2015-03-27 | Formulación tópica oftálmica de bosentan |
ESP201530409 | 2015-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016156639A1 true WO2016156639A1 (es) | 2016-10-06 |
Family
ID=55910981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2016/070197 WO2016156639A1 (es) | 2015-03-27 | 2016-03-22 | Formulación tópica oftálmica de antagonistas del receptor de la endotelina |
Country Status (9)
Country | Link |
---|---|
US (1) | US10716750B2 (es) |
EP (1) | EP3275429A1 (es) |
JP (1) | JP6768780B2 (es) |
KR (1) | KR102578102B1 (es) |
CN (2) | CN107454841A (es) |
BR (1) | BR112017019792A2 (es) |
ES (1) | ES2584534B1 (es) |
MX (1) | MX2017012428A (es) |
WO (1) | WO2016156639A1 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516259A (ja) * | 2018-03-07 | 2021-07-01 | ティンバー ファーマシューティカルズ, インコーポレイテッド | 皮膚線維症を処置するための組成物および方法 |
EP4094759A1 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
US11786510B2 (en) | 2021-04-30 | 2023-10-17 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
US11873279B2 (en) | 2020-02-06 | 2024-01-16 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924190A (zh) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种马西替坦微球及其制备方法 |
CN112569210B (zh) * | 2019-09-27 | 2023-09-15 | 盈科瑞(天津)创新医药研究有限公司 | 一种吸入用马昔腾坦溶液及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
US6770675B2 (en) * | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
JP4725699B2 (ja) * | 2002-04-08 | 2011-07-13 | ライオン株式会社 | 眼科用組成物及び眼科用組成物配合用防腐剤 |
JP5484339B2 (ja) * | 2007-10-05 | 2014-05-07 | ウェイン ステート ユニバーシティー | 合成物の持続的な放出のためのデンドリマー |
ES2719226T3 (es) * | 2007-12-04 | 2019-07-09 | Santen Sas | Composiciones que comprenden profármacos de corticosteroides tales como palmitato de dexametasona para el tratamiento de trastornos oculares |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
ES2752008T3 (es) * | 2009-10-30 | 2020-04-02 | Intratus Inc | Métodos y composiciones para la liberación sostenida de fármacos |
FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
US20140308239A1 (en) * | 2013-03-13 | 2014-10-16 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
WO2014160079A1 (en) * | 2013-03-14 | 2014-10-02 | EyeCRO, LLC | Microemulsion topical delivery platform |
AU2015264181A1 (en) * | 2014-05-23 | 2016-12-01 | Ocular Technologies Sarl | Topical formulations and uses thereof |
-
2015
- 2015-03-27 ES ES201530409A patent/ES2584534B1/es active Active
-
2016
- 2016-03-22 JP JP2018500867A patent/JP6768780B2/ja active Active
- 2016-03-22 BR BR112017019792A patent/BR112017019792A2/pt not_active Application Discontinuation
- 2016-03-22 CN CN201680018617.3A patent/CN107454841A/zh active Pending
- 2016-03-22 MX MX2017012428A patent/MX2017012428A/es unknown
- 2016-03-22 KR KR1020177027527A patent/KR102578102B1/ko active IP Right Grant
- 2016-03-22 CN CN202311521053.3A patent/CN117582396A/zh active Pending
- 2016-03-22 WO PCT/ES2016/070197 patent/WO2016156639A1/es active Application Filing
- 2016-03-22 EP EP16720451.0A patent/EP3275429A1/en active Pending
- 2016-03-22 US US15/561,922 patent/US10716750B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516259A (ja) * | 2018-03-07 | 2021-07-01 | ティンバー ファーマシューティカルズ, インコーポレイテッド | 皮膚線維症を処置するための組成物および方法 |
EP4094759A1 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
EP4050997A4 (en) * | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
US11738007B2 (en) | 2019-10-30 | 2023-08-29 | Perfuse Therapeutics, Inc. | Treatment of glaucoma using endothelin receptor antagonists |
US11873279B2 (en) | 2020-02-06 | 2024-01-16 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
US11786510B2 (en) | 2021-04-30 | 2023-10-17 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Also Published As
Publication number | Publication date |
---|---|
EP3275429A1 (en) | 2018-01-31 |
JP2018512452A (ja) | 2018-05-17 |
ES2584534B1 (es) | 2017-03-13 |
US10716750B2 (en) | 2020-07-21 |
BR112017019792A2 (pt) | 2018-05-22 |
ES2584534A1 (es) | 2016-09-28 |
CN107454841A (zh) | 2017-12-08 |
JP6768780B2 (ja) | 2020-10-14 |
KR102578102B1 (ko) | 2023-09-13 |
US20180110728A1 (en) | 2018-04-26 |
KR20170130443A (ko) | 2017-11-28 |
MX2017012428A (es) | 2018-06-19 |
CN117582396A (zh) | 2024-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2584534B1 (es) | Formulación tópica oftálmica de bosentan | |
Bertens et al. | Topical drug delivery devices: A review | |
US11931359B2 (en) | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug | |
US11951103B2 (en) | Pharmaceutical composition | |
Sahoo et al. | Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives | |
Soni et al. | Design and evaluation of ophthalmic delivery formulations | |
ES2673009T3 (es) | Plataforma de suministro tópico de microemulsiones | |
CN112135603B (zh) | 包含奈必洛尔的药物组合物 | |
JP2017519813A (ja) | 局所製剤およびその使用 | |
JP2021518352A (ja) | チモロールを含む医薬組成物 | |
EP3448388B1 (en) | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases | |
ES2905458T3 (es) | Formulaciones nanoestructuradas para la administración de silibinina y otros principios activos para el tratamiento de enfermedades oculares | |
WO2023192691A2 (en) | Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease | |
JP2013544838A (ja) | 網膜の疾患を治療するための方法 | |
CN106714803B (zh) | 眼用混悬液制剂 | |
JP2023529190A (ja) | シスチン症の治療 | |
KR102474404B1 (ko) | 다중 표적 억제제의 현탁액 조성물 | |
Virmani et al. | An overview of ocular drug delivery systemsdconventional and novel drug delivery systems | |
Schmitt | Design and development of ocular formulations for preclinical and clinical trials | |
KR20110099044A (ko) | 후안부에 유효농도의 활성제를 전달하기 위한 국소 안용액 조성물 | |
US20210052582A1 (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
JP2019163227A (ja) | 医薬組成物 | |
JPH10203979A (ja) | チアプロフェン酸を含有する抗眼炎症剤 | |
WO2005056113A1 (es) | Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva | |
CN117425480A (zh) | 用于治疗眼后段疾病的具有氧化铈纳米颗粒的眼用局部组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16720451 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018500867 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017019792 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15561922 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20177027527 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/012428 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016720451 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112017019792 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170915 |